Multi-Regional Trials Prompt FDA Interest In Sponsors' Trial Infrastructure Decisions
This article was originally published in The Pink Sheet Daily
Executive Summary
The need to ensure data quality necessitates a better understanding of how the data was collected, CDER's Robert O'Neill tells DIA.
You may also be interested in...
When Using Foreign Clinical Data, Be Prepared To Prove U.S. Applicability
When using data from clinical trials conducted outside the U.S. for an NDA, drug makers must be able to demonstrate that the data are applicable to the U.S. population and U.S. medical practice, Murray Lumpkin, FDA's deputy commissioner for international programs, said
Foreign Clinical Trials: FDA Oversight To Include More Training, Data Collection
Changes to FDA's policy for monitoring foreign clinical trials appear imminent after the Department of Health and Human Services Inspector General recommended the agency increase its oversight of data gathered outside the U.S
When Using Foreign Clinical Data, Be Prepared To Prove U.S. Applicability
When using data from clinical trials conducted outside the U.S. for an NDA, drug makers must be able to demonstrate that the data are applicable to the U.S. population and U.S. medical practice, Murray Lumpkin, FDA's deputy commissioner for international programs, said